Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13924638 | 0.84 | KMT2A (0.47) | KMT2AFPR2POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL14443972 | 0.74 | KMT2A (0.45) | KMT2APOLBALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL29990375 | 0.73 | CBLB (0.36) | KMT2A | |
| SCHEMBL10755881 | 0.71 | KMT2A (0.50) | KMT2AFPR2POLBAPOBEC3AAPOBEC3G | |
| SCHEMBL13845448 | 0.71 | KDM4E (0.45) | TSHRLMNA | |
| SCHEMBL12646807 | 0.71 | KMT2A (0.53) | KMT2AFPR2POLBPADI4ALDH1A1 | |
| SCHEMBL21783321 | 0.71 | CBLB (0.43) | KMT2AMAPK1HTT | |
| SCHEMBL23375507 | 0.69 | CBLB (0.42) | KMT2AMAPK1HTT | |
| SCHEMBL18327380 | 0.69 | CBLB (0.42) | KMT2AMAPK1HTT | |
| SCHEMBL19458462 | 0.69 | CBLB (0.42) | KMT2AMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488830-B2 | Imidazolidine-2,4-dione monomers, useful in making hydantoin polymers | RHODIA INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070025946-A1 | Polymers having heterocyclic substituent groups, monomers useful in making such polymers, and compositions containing such polymers | RHODIA OPERATIONS (FR) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070025946-A1 | Polymers having heterocyclic substituent groups, monomers useful in making such polymers, and compositions containing such polymers | MMS19, MRPS9, UNC119 | KMT2A 3138/4885FPR2 696/4885POLB 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.